Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University.
There is no effective therapy for hormone-refractory prostate cancer and a novel therapeutic modality, such as a gene therapy, should be actively pursued. Previously, Gardner and Chung conducted a phase I clinical trial of Ad-OC-TK (recombinant adenoviral vector containing osteocalcin promoter-driven herpes simplex virus thymidine kinase gene) plus VAL (valacyclovir) for the treatment of hormone-refractory prostate cancer at the University of Virginia. We report on our ongoing phase I/II clinical trial of Ad-OC-TK plus VAL for the treatment of advanced prostate cancer at the Kobe University Hospital, Japan.
Hinata
Nobuyuki
N
Division of Urology, Department of Organ Therapeutics, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Shirakawa
Toshiro
T
Terao
Shuji
S
Goda
Kazumasa
K
Tanaka
Kazushi
K
Yamada
Yuji
Y
Hara
Isao
I
Kamidono
Sadao
S
Fujisawa
Masato
M
Gotoh
Akinobu
A
D000212:Acyclovir / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000256:Adenoviridae; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy*; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods; D006785:Hospitals, University; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000235:genetics; D011471:Prostatic Neoplasms / Q000235:genetics / Q000628:therapy*; D013937:Thymidine Kinase / Q000235:genetics; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D000998:Antiviral Agents; D015675:Osteocalcin; D013937:Thymidine Kinase; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir